Press Release: Sportradar Group AG (SRAD) Facing Securities Class Action Amid Activist Short Seller Accusations of Illegal Business Model and $800 Million Market Cap Wipeout – Hagens Berman | Globe NewsWire News Distribution Service

Choose a language:

Globe NewsWire News Distribution Service

Details: Written by Globe NewsWire Press Releases; Category: Globe NewsWire News Distribution Service; Published: 29 May 2026; Created: 29 May 2026; Last Updated: 29 May 2026

SAN FRANCISCO, May 29, 2026 (GLOBE NEWSWIRE) -- Sportradar Group (NASDAQ: SRAD) faces a securities class action lawsuit, which seeks to represent investors who purchased or otherwise acquired Sportradar Class A ordinary shares between November 7, 2024 and April 21, 2026.

Posted: 2026-05-29 18:58:00

Get Full News Story On GlobeNewsWire Press Release Service

More News From This Category
Press Release: פרק חדש מתפתח ביחסי פקיסטן-סין
Sun, 31 May 2026 01:07:40 +0000

איסלאמאבאד, May 31, 2026 (GLOBE NEWSWIRE) -- משרד ההסברה והשידור הפקיסטני (MoIB) אחראי על קידום וניהול הנרטיב הרשמי סביב ביקורו של ראש ממשלת פקיסטן שהבז שריף בסין, בציון 75 שנה לכינון היחסים הדיפלומטיים.

Press Release: UPST DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Upstart Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action – UPST
Sat, 30 May 2026 22:07:39 +0000

NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Upstart Holdings, Inc. (NASDAQ: UPST) between May 14, 2025 and November 4, 2025, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.

Press Release: Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
Sat, 30 May 2026 19:07:40 +0000

ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

Press Release: Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Sat, 30 May 2026 16:07:39 +0000

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio –

Press Release: Momcozy Launches Plus Baby Wipes Built for Every “Messy Milestone”: 99% Purified Water, 8″ × 8″, Independently Certified by Intertek
Sat, 30 May 2026 13:07:40 +0000

LOS ANGELES, May 30, 2026 (GLOBE NEWSWIRE) -- Momcozy, the globally recognized mother-and-baby brand known for its wearable breast pump line, today announced the global launch of Momcozy Plus Baby Wipes. Built around the brand’s “Bring On The Mess” philosophy, the product is designed to give parents the confidence to embrace childhood’s messiest — and…

Related Bing News Results